StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) bonds

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$252.59M
$63.78M due within a year
Net debt
$130.84M
After $121.75M of cash
Implied interest rate
12.86%
FY2025 interest ÷ average debt
Interest coverage
0.9×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Xeris Biopharma's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issuedCarrying value
2025 Convertible Notes
Convertible
5.00%$86.30M–
2025 Convertible Notes, Underwriters' Option
Convertible
–$11.30M–
2028 Convertible Notes
Convertible
8.00%$33.60M$33.60M
Hayfin Tranche 1 Loan–$200.00M–
Hayfin Tranche 2 Loan–$150.00M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?